NASDAQ
26.06.26 | 21:59
2,030 US-Dollar
-0,49 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 3 | SEC Filings | ||
| 11.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Earnings Call: ALX Oncology übertrifft Gewinnprognose für Q1 2026 | 1 | Investing.com Deutsch | ||
| 09.05. | Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS | 1 | Seeking Alpha | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 08.05. | ALX Oncology: 100 % Ansprechrate in Studie bestätigt CD47-Strategie | 6 | Investing.com Deutsch | ||
| 08.05. | ALX Oncology Q1 2026 slides: 100% response validates CD47 strategy | 3 | Investing.com | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.17 beats by $0.02 | 1 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update | 650 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable... ► Artikel lesen | |
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression | 233 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the... ► Artikel lesen | |
| 17.04. | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 2 | GlobeNewswire (USA) | ||
| 13.04. | ALX Oncology names Jeff Knight as chief development officer | 1 | Investing.com | ||
| 13.04. | ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer | 252 | GlobeNewswire (Europe) | - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13... ► Artikel lesen | |
| 13.04. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Wells Fargo initiates ALX Oncology stock with overweight rating | 6 | Investing.com | ||
| 10.03. | Rüstungs-Rallye nach Iran-Angriff: Rheinmetall, Palantir, DroneShield und Harvest Technology im Fokus der Anleger | Small- & Micro Cap Investment | |||
| 09.03. | ALX ONCOLOGY HOLDINGS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.02. | ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing | 1 | Seeking Alpha | ||
| 27.02. | ALX Oncology: Aktie fällt nach verfehlter Gewinnprognose für Q4 2025 | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,906 | +1,41 % | Evotec-Aktie mit -91% - ist das die letzte Chance? | Die Evotec-Aktie hat seit ihrem Allzeithoch rund -91% an Wert verloren und zählt damit zu den größten Verlierern der vergangenen Jahre. Nach dem massiven Abverkauf bewegt sich der Kurs nun in einer... ► Artikel lesen | |
| MODERNA | 57,96 | -1,91 % | Bayer und PORR werden für Produktionsanlage ausgezeichnet | ||
| NOVAVAX | 7,750 | -0,77 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| CRISPR THERAPEUTICS | 46,750 | -2,97 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,969 | +0,68 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 14,120 | -3,42 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,300 | -1,64 % | Defence Therapeutics Inc.: Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions | Montreal, Quebec--(Newsfile Corp. - June 17, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 2,450 | -2,78 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,300 | -2,03 % | Stifel reiterates Hold on BioMarin stock, keeps $68 price target | ||
| EXELIXIS | 48,180 | +0,11 % | Truist assumes Exelixis stock coverage with Hold rating on pipeline uncertainty | ||
| SAREPTA THERAPEUTICS | 14,660 | -1,08 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| HALOZYME THERAPEUTICS | 66,06 | +0,33 % | Halozyme Therapeutics, Inc.: Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 | SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,390 | -4,37 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 147,10 | -0,61 % | Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes" | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc. - 8-K, Current Report |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-0,49 %) liegt der Kurs bei 2,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.